

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
26 September 2002 (26.09.2002)

PCT

(10) International Publication Number
WO 02/074175 A2

- (51) International Patent Classification⁷: **A61B 18/00**
- (21) International Application Number: PCT/US02/03589
- (22) International Filing Date: 7 February 2002 (07.02.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/808,624 14 March 2001 (14.03.2001) US
- (71) Applicant: **SCIMED LIFE SYSTEMS, INC.** [US/US];
One SciMed Place, Maple Grove, MN 55311 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- (72) Inventor: **DEVORE, Lauri, J.**; 17036 13th Avenue N.E., Seattle, WA 98155 (US).
- (74) Agent: **TULLETT, Rodney, C.**; Christensen O'Connor Johnson & Kindness PLLC, Suite 2800, 1420 Fifth Avenue, Seattle, WA 98101 (US).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **ULTRASOUND METHOD FOR REVASCULARIZATION AND DRUG DELIVERY**



(57) Abstract: A method and device for improving blood circulation to an area of interest within a patient's heart is described. The method comprises inserting a guidable elongated flexible ultrasound device into a patient's vasculature, applying ultrasonic energy to an area in need of improved circulation, and injecting materials such as angiogenic materials or contrasting agents into the area of interest. The device, suitable for performing the method, comprises an elongated tubular body, a distal head of the elongated tubular body for introducing ultrasonic energy to an area of interest, and a needle to deliver materials to an area of interest.

BEST AVAILABLE COPY

ULTRASOUND METHOD FOR REVASCULARIZATION AND DRUG DELIVERY

Background of the Invention

5 1. Technical Field of the Invention

The present invention relates generally to medical devices for generating an angiogenic response in an interior wall of the heart using a percutaneous myocardial revascularization (PMR) procedure. More specifically, the present invention relates to an intravascular ultrasound PMR device having a needle for supplying the heart
10 with an angiogenic material or contrasting agent.

2. Description of the Prior Art

There is a great deal of interest in improving the methods for treating cardiovascular disease. Traditionally, cardiovascular disease has been treated using
15 procedures such as cardiovascular bypass surgery, coronary angioplasty, laser angioplasty and atherectomy. These techniques generally are aimed at bypassing or opening lesions in coronary vessels so as to restore and increase blood flow to the heart. In some patients, the number of lesions is so great, or the location so remote in the patient's vasculature that restoring blood flow to the heart muscle is difficult.
20 Therefore, it is often the case that cardiovascular disease requires alternative treatment such as percutaneous myocardial revascularization (PMR).

PMR was developed as a less invasive alternative to bypass surgery. PMR was inspired in part by observations that reptilian hearts are supplied primarily by blood perfusing directly from within heart chambers. In contrast, coronary vessels
25 receiving blood from the aorta supply the human heart. PMR is performed by boring channels directly into the myocardium. This can be accomplished by a number of means including the insertion of a flexible catheter through the vasculature into the heart and boring holes into the myocardium. Positive results have been demonstrated in some human patients receiving these types of PMR treatments. These results are
30 believed to be caused in part by increased blood flowing from within a heart chamber through channels formed by PMR to the myocardial tissue. Increased blood flow to the myocardium is also believed to be caused in part by the healing response to

wound formation. Specifically, the formation of new blood vessels is believed to occur in response to the newly created wound.

Suitable PMR holes have been burned by laser, cut by mechanical means, removed by ultrasound devices, and burned by radio frequency current devices in a technique called radio frequency percutaneous myocardial revascularization (RF-PMR).

In addition, catheter based needle injections of an angiogenic material directly into the myocardium has been developed in conjunction with RF-PMR. U.S. Patent No. 6,063,082 to DeVore et al. entitled "Percutaneous Myocardial Revascularization Basket Delivery System and Radiofrequency Therapeutic Device" discloses a method in which an angiogenic material can be delivered into a hole recently burned by RF current delivered through the needle. Unfortunately, in this method the angiogenic material may seep out of the hole created by the RF-PRM electrode, thus reducing the effectiveness of the angiogenic material.

U.S. Patent No. 5,827,203 to Nita entitled "Ultrasound system and Method For Myocardial Revascularization" discloses a method that uses ultrasonic energy to accomplish PMR. Ultrasound PMR offers advantages over other PMR techniques in that the method is less invasive and that in some embodiments no tissue needs to be removed. The application of ultrasonic energy to an area of interest produces a thrombus required for angiogenesis without rupturing endocardial tissue. However, this method currently lacks the ability to deliver additional interventions, such as the delivery of angiogenic materials, to an area of interest. Thus, physicians are limited in their ability to use this method and are required to form channels in the heart wall if massaging an area of interest does not produce the desired effect. Further, if massaging an area of interest is insufficient to induce myocardial revascularization, the ultrasound device is used to bore channels. By including a means for delivering angiogenic materials, the need for using the ultrasound device to bore channels should be reduced.

New research conducted by the applicant suggests that the thrombus, caused by the application of ultrasonic energy, in and around the injury site contains the natural growth factors which cause the angiogenic response. Therefore, destruction of heart tissue, as with RF-PMR, may not be necessary to invoke an angiogenic

response. Consequently, there is a need for a method of PMR that creates a natural angiogenic response without creating unnecessary injury to an area of interest. Additionally, it would be beneficial for this method to be able to deliver additional angiogenic material to an area of interest in order to minimize both the destruction of cardiac tissue and seepage.

Summary of the Invention

A preferred embodiment of the present invention provides a minimally invasive device for the treatment of cardiovascular disease via ultrasound myocardial revascularization that additionally provides means for direct delivery of angiogenic materials. Combining ultrasound myocardial revascularization with an additional lumen for the delivery of angiogenic materials offers advantages over the prior art. Since it is believed that the thrombus contains the natural growth factors capable of facilitating an angiogenic response, this invention can accentuate the body's own natural healing ability without destroying tissue. Further, since no myocardial tissue is destroyed, seepage of angiogenic materials is minimized. Finally, a contrasting agent can be delivered through the needle to enable the physician to image an area of interest.

In one embodiment of this invention, a needle is attached to the ultrasound PMR device adjacent to the catheter along the catheter's longitudinal axis. Angiogenic materials or a contrasting agent can be delivered to an area of interest through the needle.

In another embodiment, the needle passes through the lumen of the ultrasound catheter. Angiogenic materials or a contrasting agent can be delivered to an area of interest through the needle.

Brief Description of the Drawings

Figure 1 is a perspective view of an ultrasound PMR catheter system wherein a needle is attached adjacent to the ultrasound catheter along the catheter's longitudinal axis;

Figure 2 is a schematic section of a human heart showing percutaneous revascularization of the myocardium according to the present invention; and

Figure 3 is a perspective view of an ultrasound PMR catheter system wherein a needle is attached within the lumen of the ultrasound catheter.

Detailed Description of the Preferred Embodiments

5 Referring now to the drawings wherein like reference numerals refer to like elements throughout the several views, Figure 1 illustrates a guidable elongated flexible ultrasound device for increasing blood circulation to an area of interest within the heart of a patient. The guidable elongated flexible ultrasound device includes an elongated tubular body 10 with a proximal end closest to the outside of the body and a
10 distal end closest to an area of interest within a patient's heart. In the preferred embodiment, the elongated tubular body 10 is constructed of flexible material to easily pass through turns of the vasculature. The elongated tubular body 10 has at least one lumen 12, extending along the longitudinal axis 14 thereof.

The distal head 16 of the elongated tubular body includes an ultrasonic
15 catheter device that can be connected to a signal generator by an ultrasound transmission lead 18. As such, when a signal generator sends ultrasonic energy through the ultrasound transmission lead 18, ultrasonic energy will pass through the distal head 16 to an area of interest and can be used to massage the myocardium 30. More specifically, the ultrasound transmission lead 18 serves to transmit ultrasonic
20 energy from the proximal end of the elongated flexible ultrasound device to the distal head 16 of the elongated tubular body 10, and then to an area of interest.

The guidable elongated flexible ultrasound device can reach an area of interest by first inserting a guidewire 19 into the patient's vasculature and passing the elongated tubular body 10 over said guidewire 19. In the preferred embodiment, the
25 guidewire 19 can pass through a lumen within the elongated tubular body ranging from the elongated tubular body's far proximal end through the distal head and then through a lumen 21 within said distal head. One skilled in the art can insert the guidewire 19 through a patient's vasculature and into the patient's heart to an area of interest. Then, the elongated tubular body 10 can be passed over said guidewire 19
30 through a lumen therein to an area of interest.

Mounted adjacent to the elongated tubular body 10 is a needle 20 with a lumen 22 for injecting material 24 near a thrombus 26. In the preferred embodiment, the

needle is constructed of stainless steel. The lumen 22 of the needle 20 is of sufficient diameter to allow passage of angiogenic materials or contrasting agents. Angiogenic materials comprise a plethora of substances including but not limited to pharmaceutically active compounds, nucleic acids (including polynucleotide sequences), peptides (including polypeptides and proteins), oligonucleotides, ribozymes, anti-sense genes, DNA compacting agents, and gene/vector systems (i.e., anything that allows for the uptake and expression of nucleic acids).

For example, nucleic acids that may comprise angiogenic materials include anti-sense DNA and RNA, DNA coding for an anti-sense RNA, or DNA coding for tRNA, or rRNA to replace defective or deficient endogenous molecules. The angiogenic polynucleotides may also code for therapeutic peptides, polypeptides and proteins. A polypeptide is understood to be any translational product of a polynucleotide regardless of size, and whether glycosylated or not.

Therapeutic polypeptides that may act as angiogenic factors including acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor α and β , platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor α , hepatocyte growth factor and insulin like growth factor; growth factors; cell cycle inhibitors including CDK inhibitors; thymidine kinase ("TK") and other agents useful for interfering with cell proliferation, including agents for treating malignancies; and combinations thereof.

In another embodiment of the present invention, angiogenic materials may include a viral vector having linked thereto an exogenous nucleic acid sequence. "Exogenous nucleic acid sequence" is used herein to mean a sequence of nucleic acids that is exogenous to the virus from which the vector is derived. The concentration of the viral vector, preferably an adenoviral vector, is at least about 10^{10} plaque forming units ("p.f.u."), or limited by the concentration that results in an undesirable immune response from a patient.

Contrasting agents comprise substances including but not limited to those that enable a physician performing the method or using the device to accumulate information useful for completing or evaluating the procedure. Example of contrasting agents include but are not limited to saline (0.9% NaCl) that can flood the

tip of the guidable elongated flexible ultrasound device so as to enable visualization of an area of interest or the device's location within the vasculature, radioactive or radiolabeled magnetic compounds useful for tracing during or after performing the method, and anti-thrombin or blood thinning compounds (including heparin, heparin derivatives, urokinase, dextrophenylalanine proline arginine chloromethylketone, rapamycin, probucol, and verapamil).

Applying ultrasonic energy to the endocardial layer 28 of the myocardium 30 generates the thrombus 26. One skilled in the art can massage the myocardium 30 with ultrasonic energy emitted through the distal head 16 of the elongated tubular body 10. When ultrasonic energy is applied to the myocardium 30, it causes relaxation of the cardiac muscle and vasodilation (relaxation of the vasculature that may result in increased blood flow to the area wherein ultrasonic energy is used upon). In an embodiment of the invention, when the myocardium 30 is massaged, preferably no heart tissue or an insignificant amount is removed from the endocardium 28. A sufficient amount of massaging can lead to the formation of at least one thrombus 26 wherein clotting and wound healing can take place and lead to myocardial revascularization. Once a thrombus is formed, the needle 20 can be used to deliver angiogenic materials or contrasting agents that may accentuate the body's natural ability to promote revascularization and/or wound healing.

The guidable elongated flexible ultrasound device also includes an endoscopic visualization device 32 for visualizing an area of interest. The device extends longitudinally through the lumen 22 of the elongated tubular body 10 and comprises an outer sheath having at least one image transmitting optical fiber bundle and possibly one or more additional fiber bundles extending longitudinally throughout. The image transmitting optical fiber bundle is encircled by a plurality of light transmitting optical fiber bundles that also extend longitudinally along the outer sheath. At its proximal end, the visualization device is connected to at least one machine that may be suitable for allowing a physician skilled in the art to visualize an area of interest or the present location within the vasculature of the guidable elongated flexible ultrasound device.

Figure 2 illustrates a schematic of a human heart 40 showing percutaneous revascularization of the myocardium 30 using the invention drawn in Figure 1. The

distal head 16 of the elongated tubular body 10 is inserted percutaneously into a major blood vessel (such as the femoral arterial or another peripheral vessel), into and through the aorta 44 to the heart 40, and into a ventricle 46 to an area in need of increased blood circulation 48. Ultrasonic energy from the distal head 16 is used to
5 massage an area of interest so as to generate a thrombus. Angiogenic materials or contrasting agents can then be injected through the needle 20 mounted adjacent to the elongated tubular body 10 through the endocardium 28 and into or near the thrombus.

Figure 3 illustrates an embodiment of a guidable elongated flexible ultrasound device similar to that drawn in Figure 1. The guidable elongated flexible ultrasound
10 device includes an elongated tubular body 110 with at least one lumen 112, with a proximal end closest to the outside of the body and a distal end closest to an area of interest within a patient's heart. The distal head 116 of the elongated tubular body includes an ultrasonic catheter device that can be connected to a signal generator by an ultrasound transmission lead 18. Ultrasonic energy can pass through the distal
15 head 116 via the ultrasound transmission lead to an area of interest and can be used to massage the myocardium 30. A sufficient amount of massaging can lead to the formation of at least one thrombus 26 wherein clot clotting and wound healing can take place and lead to myocardial revascularization.

The guidable elongated flexible ultrasound device also includes an
20 endoscopic visualization device 32 for visualizing said area of interest. The device extends longitudinally through the lumen 122 of the elongated tubular body 110 and comprises an outer sheath having at least one image transmitting optical fiber bundle and possibly one or more additional fiber bundles extending longitudinally throughout. At its proximal end, the visualization device can be connected to at least
25 one machine suitable for allowing a physician skilled in the art to visualize an area of interest or the present location within the vasculature of the guidable elongated flexible ultrasound device.

The guidable elongated flexible ultrasound device can reach an area of interest by first inserting a guidewire 19 into the patient's vasculature and passing the
30 elongated tubular body 110 over said guidewire 19. In the preferred embodiment, the guidewire 19 can pass through a lumen within the elongated tubular body ranging from the elongated tubular body's far proximal end through the distal head and then

through a lumen 121 within said distal head. Then, the elongated tubular body 110 can be passed over said guidewire 19 through a lumen therein to an area of interest.

In the current embodiment, a needle 120 for injecting materials 124 into or near a thrombus 26 is mounted within the lumen 112 of the elongated tubular body 110 and passes through the distal head 116. The distal head 116 still retains its ability to transmit ultrasonic energy so as to generate at least one thrombus 26 within the myocardium 30. The lumen 122 of the needle 120 is of sufficient diameter to allow passage of angiogenic materials or contrasting agent. Angiogenic materials may include pharmaceutically active compounds, nucleic acids (including polynucleotide sequences), peptides (including polypeptides and proteins), oligonucleotides, ribozymes, anti-sense genes, DNA compacting agents, and gene/vector systems (i.e., anything that allows for the uptake and expression of nucleic acids) including but not limited to those listed previously. Contrasting agents may include saline, radioactive compounds, and anti-thrombin compounds including but not limited to those listed previously.

Numerous advantages of the invention covered by this document have been set forth in the foregoing description. It will be understood, however, that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of parts without exceeding the scope of the invention. The invention's scope is, of course, defined in the language in which the appended claims are expressed.

What is claimed is:

1. A method for improving blood circulation to an area of interest in a heart muscle of a patient, said method comprising the steps of:

inserting a guidable elongated flexible ultrasound device into said patient's vasculature, said guidable elongated flexible ultrasound device having an elongate lumen, a distal end, a proximal end, a distal head mounted on said distal end, and a needle mounted to said elongated tubular body in fluid communication with said lumen;

guiding said distal head to said area of interest in said heart muscle;

applying ultrasonic energy via said distal head to said area of interest; and

injecting a material into said area of interest with said needle.

2. The method of claim 1, wherein said material is an angiogenic material.

3. The method of claim 1, wherein said material is a contrasting agent.

4. The method of claim 1, wherein the step of applying said ultrasonic energy further comprises the step of massaging said area of interest without removing any portion of said heart muscle at said area of interest.

5. The method of claim 1, wherein said needle is attached adjacent to said distal head.

6. The method of claim 1, wherein said needle extends from said distal head.

7. The method of claim 1, wherein the step of inserting said guidable elongated flexible ultrasound device further comprises the step of inserting a guidewire into said patient's vasculature and passing said guidable elongated flexible ultrasound device over said guidewire.

8. The method of claim 1, wherein said guidable elongated flexible ultrasound device includes an endoscopic visualization device for visualizing said area of interest.

9. A method for improving blood circulation to an external area of interest in a heart muscle of a patient, said method comprising the steps of:

providing a guidable elongated flexible ultrasound device into said patient's chest cavity, said guidable elongated flexible ultrasound device having an elongate lumen, a distal end, a proximal end, a distal head mounted on said distal end, and a needle with a lumen mounted to said elongated tubular body in fluid communication with said lumen;

guiding said distal head within said patient's chest cavity to contact said exterior area of interest of said heart muscle;

applying ultrasonic energy via said distal head to said external area of interest; and

injecting a material into said area of interest with said needle.

10. The method of claim 9, wherein said material is an angiogenic material.

11. The method of claim 9, wherein said material is a contrasting agent.

12. The method of claim 9, wherein the step of applying said ultrasonic energy further comprises the step of massaging said external area of interest without removing any portion of said heart muscle at said external area of interest.

13. The method of claim 9, wherein said needle is attached adjacent to said distal head.

14. The method of claim 9, wherein said needle extends from said distal head.

15. A guidable elongated flexible ultrasound device for increasing the blood circulation to an area of interest in a heart muscle of a patient comprising:

an elongated tubular body having a lumen, a longitudinal axis, a distal end and a proximal end;

a distal head mounted on said distal end for introducing ultrasonic waves to said area of interest; and

a needle for injecting a material into said area of interest, said needle mounted to said elongated tubular body substantially parallel to said longitudinal axis of said tubular body.

16. The guidable elongated flexible ultrasound device as recited in claim 15, wherein said material is an angiogenic material.

17. The guidable elongated flexible ultrasound device as recited in claim 16, wherein said material is a contrasting agent.

18. The guidable elongated flexible ultrasound device of claim 15, wherein said needle is attached adjacent to said elongated tubular body.

19. The guidable elongated flexible ultrasound device of claim 15, wherein said needle is attached to said elongated tubular body within said lumen of said elongated tubular body.

20. The guidable elongated flexible ultrasound device of claim 15, further comprising a guidewire for inserting into said patient's vasculature and passing said guidable elongated flexible ultrasound device over said guidewire.




FIG. 1




FIG. 2




FIG. 3

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 September 2002 (26.09.2002)

PCT

(10) International Publication Number
WO 02/074175 A3

(51) International Patent Classification⁷: **A61B 17/22**,
A61N 7/00

(21) International Application Number: PCT/US02/03589

(22) International Filing Date: 7 February 2002 (07.02.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/808,624 14 March 2001 (14.03.2001) US

(71) Applicant: **SCIMED LIFE SYSTEMS, INC.** [US/US];
One SciMed Place, Maple Grove, MN 55311 (US).

(72) Inventor: **DEVORE, Lauri, J.**; 17036 13th Avenue N.E.,
Seattle, WA 98155 (US).

(74) Agent: **TULLETT, Rodney, C.**; Christensen O'Connor
Johnson & Kindness PLLC, Suite 2800, 1420 Fifth Avenue,
Seattle, WA 98101 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report

(88) Date of publication of the international search report:
27 February 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **ULTRASOUND SYSTEM AND METHOD FOR REVASCULARIZATION AND DRUG DELIVERY**



(57) Abstract: A method and device for improving blood circulation to an area of interest within a patient's heart is described. The method comprises inserting a guidable elongated flexible ultrasound device into a patient's vasculature, applying ultrasonic energy to an area in need of improved circulation, and injecting materials such as angiogenic materials or contrasting agents into the area of interest. The device, suitable for performing the method, comprises an elongated tubular body, a distal head of the elongated tubular body for introducing ultrasonic energy to an area of interest, and a needle to deliver materials to an area of interest.

WO 02/074175 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/03589

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61B17/22 A61N7/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61B A61N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	WO 00 16704 A (EKOS CORP) 30 March 2000 (2000-03-30) page 5, line 6,7,20-24 page 9, line 27 -page 10, line 3,16-24 page 11, line 3-20,28 -page 12, line 11; claims 1,13,28; figures 1A,2A,2C,6	15-17, 19,20 18
X	WO 00 18305 A (STAMBAUGH BRUCE D ;NGUYEN HIEN V (US); HEARTEN MEDICAL (US); LAUFE) 6 April 2000 (2000-04-06) page 10, line 3-19 page 11, line 11-17; claims 1,4,5,12,13; figure 3	15,16, 19,20
X	WO 97 29701 A1 (FENSTER MAIER ET AL) 21 August 1997 (1997-08-21) page 10, line 1 -page 11, line 10 figure 1C	15-17, 19,20
	--- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 July 2002

Date of mailing of the international search report

16/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Reinbold, F

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/03589

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6 095 981 A (MCGAHAN JOHN P) 1 August 2000 (2000-08-01)	18
A	column 1, line 60 -column 2, line 2 column 3, line 1-18; claim 1; figure 1	15
A	US 6 102 867 A (RANALLETTA JOSEPH V ET AL) 15 August 2000 (2000-08-15) column 3, line 35-52 column 5, line 15 -column 6, line 27; figures 1,2	15,18
P,X	WO 01 97698 A (AN GO GEN INC ;STEWART DUNCAN (CA)) 27 December 2001 (2001-12-27) page 2, line 26 -page 3, line 28 page 8, line 17-23; figures 1,4	15-17, 19,20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 02/03589

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-14
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy or surgery
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; It is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/03589

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0016704	A	30-03-2000	US 6312402 B1 WO 0016704 A1	06-11-2001 30-03-2000
WO 0018305	A	06-04-2000	US 6283935 B1 AU 6278199 A WO 0018305 A1 US 2001025185 A1	04-09-2001 17-04-2000 06-04-2000 27-09-2001
WO 9729701	A1	21-08-1997	AU 715925 B2 AU 1170197 A AU 712539 B2 AU 1206697 A AU 1616697 A AU 1616797 A AU 1616897 A AU 721034 B2 AU 1616997 A AU 709081 B2 AU 1958997 A CA 2242353 A1 CA 2242356 A1 EP 0888082 A1 EP 0888150 A1 EP 0888086 A1 EP 0910300 A1 WO 9724983 A2 WO 9725101 A2 WO 9729699 A1 WO 9729700 A1 WO 9729682 A1 JP 2000507118 T JP 2001500749 T WO 9729709 A1 US 2002055674 A1 US 6332089 B1 US 2001003790 A1	10-02-2000 01-08-1997 11-11-1999 01-08-1997 02-09-1997 02-09-1997 02-09-1997 22-06-2000 02-09-1997 19-08-1999 02-09-1997 17-07-1997 17-07-1997 07-01-1999 07-01-1999 07-01-1999 28-04-1999 17-07-1997 17-07-1997 21-08-1997 21-08-1997 21-08-1997 13-06-2000 23-01-2001 21-08-1997 09-05-2002 18-12-2001 14-06-2001
US 6095981	A	01-08-2000	NONE	
US 6102867	A	15-08-2000	US 5931787 A	03-08-1999
WO 0197698	A	27-12-2001	AU 6887901 A WO 0197698 A1	02-01-2002 27-12-2001

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.